Pfizer Forecast, price target & analysts
Pfizer Target price 2026 - Analyst rating & recommendation
Pfizer Classifications & Recommendation
Pfizer Price Target
| Target Price | $28.56 |
| Price | $28.12 |
| Potential |
1.56%
register free of charge
|
| Number of Estimates | 31 |
|
31 Analysts have issued a price target Pfizer 2027 .
The average Pfizer target price is $28.56.
This is
1.56%
register free of charge
$37.54
33.49%
register free of charge
$24.24
13.80%
register free of charge
|
|
| A rating was issued by 36 analysts: 14 Analysts recommend Pfizer to buy, 20 to hold and 2 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Pfizer stock has an average upside potential 2027 of
1.56%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Billion $ | 62.58 | 62.92 |
| 1.65% | 0.55% | |
| EBITDA Margin | 39.43% | 38.78% |
| 13.96% | 1.65% | |
| Net Margin | 12.42% | 27.20% |
| 1.62% | 119.04% |
30 Analysts have issued a sales forecast Pfizer 2026 . The average Pfizer sales estimate is
This results in the following potential growth metrics:
15 Analysts have issued an Pfizer EBITDA forecast 2026. The average Pfizer EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
29 Pfizer Analysts have issued a net profit forecast 2026. The average Pfizer net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 1.36 | 3.00 |
| 3.55% | 120.59% | |
| P/E | 9.36 | |
| EV/Sales | 3.37 |
29 Analysts have issued a Pfizer forecast for earnings per share. The average Pfizer EPS is
This results in the following potential growth metrics and future valuations:
Current Pfizer Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HSBC |
Locked
➜
Locked
|
Locked | Sep 10 2026 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Aug 07 2026 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Jul 13 2026 |
| BMO Capital |
Locked
➜
Locked
|
Locked | Jul 13 2026 |
| B of A Securities |
Locked
➜
Locked
|
Locked | Jul 10 2026 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Jul 08 2026 |
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Jul 06 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
HSBC:
Locked
➜
Locked
|
Sep 10 2026 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Aug 07 2026 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Jul 13 2026 |
|
Locked
BMO Capital:
Locked
➜
Locked
|
Jul 13 2026 |
|
Locked
B of A Securities:
Locked
➜
Locked
|
Jul 10 2026 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Jul 08 2026 |
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Jul 06 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
